Induction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of head and neck: A phase II trial

Cancer

Volumn 89, Issue 12, 2000, Pages 2587-2596

  Grecula, John C ^a   Smith, Roy E ^b   Rhoades, Chris A ^b   Sharma, Pramod ^b   Agrawal, Amit ^a   Zhang, Hong ^c   Allen, James ^a   Goldman, Federico P ^d   Young, Donn ^e   Schuller, David E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NSABP Foundation Inc   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Pulmonary and Critical Care Division   (United States)

^e Division of Pulmonary Medicine and Critical Care ^*  (United States)

Author keywords

Carcinomas; Induction; Paclitaxel; Radiation

Indexed keywords

CIMETIDINE; COBALT 60; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COBALT THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034671797     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001215)89:12<2587::AID-CNCR11>3.0.CO;2-R     Document Type: Article

References (56)

1. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer
2. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup Study 0034
3. Combined radiation and surgery in the management of advanced head and neck cancer: Final report of study 73-03 of the Radiation Therapy Oncology Group
4. Combined-modality therapy for head and neck cancer
5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
6. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group
7. Combination therapy protocol for stage III and stage IV carcinoma of the oral cavity, oropharynx, and hypopharynx
8. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group
9. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation: Results from 5 to 10 years
10. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program
11. Five year results of cisplatin and fluorouracil infusion in head and neck cancer
12. The emerging role of paclitaxel in breast cancer therapy
13. Paclitaxel administered by 1-hour infusion-preliminary results of a phase I/II trial comparing two schedules
14. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
15. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
16. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
17. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
18. Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: Activity independent of prior anthracycline response
19. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
20. Promotion of microtubule assembly in vitro by taxol
21. Taxol stabilizes microtubules in mouse fibroblast cells
22. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines
23. Preclinical pharmacology and Phase I clinical trials
24. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
25. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
26. A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies
27. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma
28. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pre-treated solid tumors: Results of a phase I/II trial
29. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA390)
30. Head and neck
31. Reporting results of cancer treatment
32. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria
33. Nonparametric estimation from incomplete observations
34. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
35. Cisplatin and mitoguazone: An induction chemotherapy regimen in advanced head and neck cancer
36. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
37. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma
38. Preoperative chemotherapy followed by esophagectomy compared with surgery alone in the treatment of squamous cell carcinoma of the esophagus
39. Induction chemotherapy in advanced head and neck cancer
40. Long term follow-up on an intensified treatment regimen for advanced resectable head and neck squamous cell carcinomas
41. Intensification regimen 2 for advanced head and neck squamous cell carcinomas
42. Postoperative complications in patients receiving suramin therapy
43. The effect of suramin on healing adult rodent dermal wounds
44. The effect of antineoplastic agents on the healing of small intestinal anastomoses in the rat
45. Reversal of doxorubicin-impaired wound healing using triad compound
46. The effect of intermittent-release intraperitoneal chemotherapy on wound healing
47. Randomized phase II trial of weekly methotrexate (MTX) versus two schedules of triweekly paclitaxel (taxol) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)
48. Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer
49. Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: Preliminary results of two pilot trials using paclitaxel and cisplatin
50. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinomas
51. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
52. Paclitaxel (Taxol)/Ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
53. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck
54. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (Stage III and IV)
55. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
56. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study